Jimmy J Caudell1, Julie L Locher, James A Bonner. 1. Department of Radiation Oncology, University of Mississippi Medical Center, 350 Woodrow Wilson Dr, Ste 1600, Jackson, MS 39213, USA. jjcaudell@gmail.com
Abstract
OBJECTIVE: To assess the impact of prolonged diagnosis-to-treatment interval (DTI) that falls in the time frame associated with the increasing complexity of planning treatment for patients with locoregionally advanced head and neck cancer (LAHNC). DESIGN: Retrospective study. SETTING: The University of Alabama at Birmingham. PATIENTS: An institutional database was searched for all patients with LAHNC who were treated with radiotherapy between 1995 and 2007 at the University of Alabama at Birmingham. After patients with prior treatment for head and neck cancer (including surgery or neoadjuvant chemotherapy), patients younger than 18 years, and patients with stage I or II tumors were excluded, 427 patients remained for analysis. MAIN OUTCOME MEASURES: The DTI was defined as the time in days between the date that a biopsy specimen showing malignancy was obtained and the first day of radiotherapy. RESULTS: The median DTI was 34 days (range, 7-441 days). A longer DTI was not significantly associated with locoregional control (P = .11), distant metastases-free survival (P = .32), or overall survival (P = .07). CONCLUSION: A prolonged DTI did not appear to adversely affect outcomes in this cohort of patients with LAHNC.
OBJECTIVE: To assess the impact of prolonged diagnosis-to-treatment interval (DTI) that falls in the time frame associated with the increasing complexity of planning treatment for patients with locoregionally advanced head and neck cancer (LAHNC). DESIGN: Retrospective study. SETTING: The University of Alabama at Birmingham. PATIENTS: An institutional database was searched for all patients with LAHNC who were treated with radiotherapy between 1995 and 2007 at the University of Alabama at Birmingham. After patients with prior treatment for head and neck cancer (including surgery or neoadjuvant chemotherapy), patients younger than 18 years, and patients with stage I or II tumors were excluded, 427 patients remained for analysis. MAIN OUTCOME MEASURES: The DTI was defined as the time in days between the date that a biopsy specimen showing malignancy was obtained and the first day of radiotherapy. RESULTS: The median DTI was 34 days (range, 7-441 days). A longer DTI was not significantly associated with locoregional control (P = .11), distant metastases-free survival (P = .32), or overall survival (P = .07). CONCLUSION: A prolonged DTI did not appear to adversely affect outcomes in this cohort of patients with LAHNC.
Authors: Luke H DeGraaff; Alexis J Platek; Austin J Iovoli; Kimberly E Wooten; Hassan Arshad; Vishal Gupta; Ryan P McSpadden; Moni Abraham Kuriakose; Wesley L Hicks; Mary E Platek; Anurag K Singh Journal: Oral Oncol Date: 2019-07-30 Impact factor: 5.337
Authors: Arash O Naghavi; Michelle I Echevarria; G Daniel Grass; Tobin J Strom; Yazan A Abuodeh; Kamran A Ahmed; Youngchul Kim; Andy M Trotti; Louis B Harrison; Kosj Yamoah; Jimmy J Caudell Journal: Cancer Date: 2016-08-01 Impact factor: 6.860
Authors: Sonam Sharma; Justin Bekelman; Alexander Lin; J Nicholas Lukens; Benjamin R Roman; Nandita Mitra; Samuel Swisher-McClure Journal: Oral Oncol Date: 2016-03-16 Impact factor: 5.337
Authors: Antonieta Medina-Lara; Bogdan Grigore; Ruth Lewis; Jaime Peters; Sarah Price; Paolo Landa; Sophie Robinson; Richard Neal; William Hamilton; Anne E Spencer Journal: Health Technol Assess Date: 2020-11 Impact factor: 4.014
Authors: Tyler A Janz; Joanne Kim; Elizabeth G Hill; Katherine Sterba; Graham Warren; Anand K Sharma; Terry A Day; Chanita Hughes-Halbert; Evan M Graboyes Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-12-01 Impact factor: 6.223
Authors: R D Neal; P Tharmanathan; B France; N U Din; S Cotton; J Fallon-Ferguson; W Hamilton; A Hendry; M Hendry; R Lewis; U Macleod; E D Mitchell; M Pickett; T Rai; K Shaw; N Stuart; M L Tørring; C Wilkinson; B Williams; N Williams; J Emery Journal: Br J Cancer Date: 2015-03-31 Impact factor: 7.640
Authors: Henrieke W Schutte; Guido B van den Broek; Stefan C A Steens; Rosella P M G Hermens; Jimmie Honings; Henri A M Marres; Matthias A W Merkx; Willem L J Weijs; Anne I J Arens; Adriana C H van Engen-van Grunsven; Carla M L van Herpen; Johannes H A M Kaanders; Frank J A van den Hoogen; Robert P Takes Journal: Cancer Date: 2020-07-07 Impact factor: 6.860